CLPTM1 Antibody (G-7): sc-374619

CLPTM1 Antibody (G-7) is a mouse monoclonal IgG2a kappa light chain antibody that detects CLPTM1 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). CLPTM1 (G-7) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CLPTM1 protein plays a crucial role in the development of the oral-facial region, particularly in the context of cleft lip and palate, which are among the most common congenital defects affecting approximately one in every 750-1,000 live births. Understanding CLPTM1 function is vital, as CLPTM1 is implicated in the genetic and environmental factors contributing to these birth defects. Additionally, CLPTM1 is part of a family of transmembrane proteins associated with cleft lip and palate, which includes the cisplatin resistance-related protein (CRR9), known for its involvement in CDDP-induced apoptosis. The strong homology of CLPTM1 to two genes in Caenorhabditis elegans further underscores its evolutionary significance and potential functional conservation across species.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CLPTM1 Antibody (G-7) References:

1. A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis.  |  Yamamoto, K., et al. 2001. Biochem Biophys Res Commun. 280: 1148-54. PMID: 11162647
2. Gene/environment causes of cleft lip and/or palate.  |  Murray, JC. 2002. Clin Genet. 61: 248-56. PMID: 12030886
3. Identification of inactivating mutations in the JAK1, SYNJ2, and CLPTM1 genes in prostate cancer cells using inhibition of nonsense-mediated decay and microarray analysis.  |  Rossi, MR., et al. 2005. Cancer Genet Cytogenet. 161: 97-103. PMID: 16102578
4. Mutation analysis of CLPTM 1 and PVRL 1 genes in patients with non-syndromic clefts of lip, alveolus and palate.  |  Turhani, D., et al. 2005. J Craniomaxillofac Surg. 33: 301-6. PMID: 16122939
5. Genetic evidence for the role of loci at 19q13 in cleft lip and palate.  |  Warrington, A., et al. 2006. J Med Genet. 43: e26. PMID: 16740910
6. TERT-CLPTM1 locus polymorphism (rs401681) is associated with the prognosis of hepatocellular carcinoma.  |  Lee, HW., et al. 2017. Onco Targets Ther. 10: 4853-4858. PMID: 29042796
7. Clptm1 Limits Forward Trafficking of GABAA Receptors to Scale Inhibitory Synaptic Strength.  |  Ge, Y., et al. 2018. Neuron. 97: 596-610.e8. PMID: 29395912
8. Clptm1, a new target in suppressing epileptic seizure by regulating GABAA R-mediated inhibitory synaptic transmission in a PTZ-induced epilepsy model.  |  Zhang, XL., et al. 2023. Kaohsiung J Med Sci. 39: 61-69. PMID: 36519412
9. De novo CLPTM1 variants with reduced GABAA R current response in patients with epilepsy.  |  Liu, N., et al. 2023. Epilepsia. 64: 2968-2981. PMID: 37577761
10. Haploinsufficiency of GABAA Receptor-Associated Clptm1 Enhances Phasic and Tonic Inhibitory Neurotransmission, Suppresses Excitatory Synaptic Plasticity, and Impairs Memory.  |  Ge, Y. and Craig, AM. 2024. J Neurosci. 44: PMID: 38942471
11. The major locus for multifactorial nonsyndromic cleft lip maps to mouse chromosome 11.  |  Juriloff, DM. and Mah, DG. 1995. Mamm Genome. 6: 63-9. PMID: 7767007
12. Characterization of a novel gene disrupted by a balanced chromosomal translocation t(2;19)(q11.2;q13.3) in a family with cleft lip and palate.  |  Yoshiura, K., et al. 1998. Genomics. 54: 231-40. PMID: 9828125

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CLPTM1 Antibody (G-7) has 3 citations in a variety of scientific publications.

Primary antibodies like Anti-CLPTM1 Antibody (G-7) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CLPTM1 Antibody (G-7) Specifications

Alternate Product Name: CLPTM1

Product Clone Name: G-7

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 21-201

Epitope Target: CLPTM1

Epitope Species: human

Product Reactivity/Detection: CLPTM1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 3 citations in various scientific publications

Available Conjugates/Forms for CLPTM1 Antibody (G-7): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin